Paradoxical growth of candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1071-1083

  Rueda, Cristina ^a   Cuenca Estrella, Manuel ^a   Zaragoza, Oscar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; CASPOFUNGIN; CHITIN; ECHINOCANDIN;

ADAPTATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CELL PROTECTION; CELL SIZE; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME INHIBITION; FKS GENE; FUNGAL CELL WALL; FUNGAL GENE; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; GALLERIA MELLONELLA; MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA ALBICANS; CELL WALL; CELLS, CULTURED; CHITIN; CULTURE MEDIA, CONDITIONED; ECHINOCANDINS; LARVA; MACROPHAGES; MICE; MOTHS; VIRULENCE;

EID: 84893457298     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00946-13     Document Type: Article

References (55)

1. Bouza E, Munoz P. 2008. Epidemiology of candidemia in intensive care units. Int. J. Antimicrob. Agents 32(Suppl 2):S87-S91. http://dx.doi.org/10. 1016/S0924-8579(08)70006-2.
2. Holt SL, Drew RH. 2011. Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections. Am. J. Health Syst. Pharm. 68:1207-1220. http://dx.doi.org/10.2146/ajhp100456.
3. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. http://dx.doi.org/10.1016/S0140-6736(03)14472-8.
4. Kurtz MB, Douglas CM. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86. http://dx.doi.org/10.1080/ 02681219780000961.
5. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312. http://dx.doi.org/10.1128/AAC.00262-08.
6. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
7. Walker LA, Gow NA, Munro CA. 2010. Fungal echinocandin resistance. Fungal Genet. Biol. 47:117-126. http://dx.doi.org/10.1016/j.fgb.2009.09.003.
8. Stevens DA, Espiritu M, Parmar R. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411. http://dx.doi.org/ 10.1128/AAC.48.9.3407-3411.2004.
9. Bayegan S, Majoros L, Kardos G, Kemeny-Beke A, Miszti C, Kovacs R, Gesztelyi R. 2010. In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin. J. Microbiol. 48:170-173. http://dx.doi.org/10.1007/s12275-010- 9221-y.
10. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. 2007. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259. http://dx.doi.org/10.1128/AAC.00095-07.
11. Fleischhacker M, Radecke C, Schulz B, Ruhnke M. 2008. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur. J. Clin. Microbiol. Infect. Dis. 27:127-131. http://dx.doi.org/10.1007/ s10096-007-0411-4.
12. Marine M, Pastor FJ, Sahand IH, Ponton J, Quindos G, Guarro J. 2009. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. Antimicrob. Agents Chemother. 53: 5297-5299. http://dx.doi.org/10.1128/AAC.00980-09.
13. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51:173-178. http://dx.doi.org/10.1016/j.diagmicrobio.2004.10.006.
14. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. 2005. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. 49:5146-5148. http://dx.doi.org/10.1128/AAC.49.12.5146-5148. 2005.
15. Bizerra FC, Melo AS, Katchburian E, Freymuller E, Straus AH, Takahashi HK, Colombo AL. 2011. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob. Agents Chemother. 55:302-310. http://dx.doi.org/10.1128/AAC.00633- 10.
16. Khlif M, Bogreau H, Michel-Nguyen A, Ayadi A, Ranque S. 2010. Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes. Antimicrob. Agents Chemother. 54:1365-1368. http://dx.doi.org/10.1128/AAC.00530-09.
17. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. 2011. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob. Agents Chemother. 55:2641-2647. http://dx.doi.org/10.1128/AAC.00999-10.
18. Soczo G, Kardos G, Varga I, Kelentey B, Gesztelyi R, Majoros L. 2007. In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob. Agents Chemother. 51:4474-4476. http://dx.doi.org/10.1128/AAC.00880-07.
19. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161. http://dx.doi.org/10.1128/AAC.00563-06.
20. Munro CA, Selvaggini S, de Bruijn I, Walker L, Lenardon MD, Gerssen B, Milne S, Brown AJ, Gow NA. 2007. The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol. Microbiol. 63:1399-1413. http://dx.doi.org/10.1111/j.1365-2958.2007.05588.x.
21. Lee KK, MacCallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NA, Munro CA. 2012. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob. Agents Chemother. 56:208-217. http://dx.doi.org/10.1128/AAC.00683-11.
22. Walker LA, Gow NA, Munro CA. 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob. Agents Chemother. 57:146-154. http://dx.doi.org/10.1128/AAC.01486-12.
23. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4:e1000040. http://dx.doi.org/10.1371/journal.ppat.1000040.
24. White TJ, Bruns TD, Lee SB. 1990. Amplification and direct sequencing of fungal ribosomalRNAgenes for phylogenetics, p 315-322. In Innis MA, Gelfald DH, Sninsky JJ, White TJ (ed), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.
25. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
26. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Donnelly JP, Dromer F, Fegeler W, Lass-Florl C, Moore C, Richardson M, Sandven P, Veledraki A, Verweij P. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405. http://dx.doi.org/10.1111/j.1469-0691.2007.01935.x.
27. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Fegeler W, Gaustad P, Klimko N, Lass-Florl C, Moore C, Richardson M, Schmalrek A, Stenderup J, Veledraki A, Verweij P. 2008. EUCAST technical note on fluconazole. Clin. Microbiol. Infect. 14:193-195. http://dx.doi.org/10.1111/j.1469-0691.2007.01899. x.
28. Barchiesi F, Spreghini E, Tomassetti S, Arzeni D, Giannini D, Scalise G. 2005. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49: 4989-4992. http://dx.doi.org/10.1128/AAC.49.12.4989-4992.2005.
29. Clancy CJ, Huang H, Cheng S, Derendorf H, Nguyen MH. 2006. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob. Agents Chemother. 50: 2569-2572. http://dx.doi.org/10. 1128/AAC.00291-06.
30. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
31. Tang CM, Cohen J, Holden DW. 1992. An Aspergillus fumigatus alkaline protease mutant constructed by gene disruption is deficient in extracellular elastase activity. Mol. Microbiol. 6:1663-1671. http://dx.doi.org/10.1111/j. 1365-2958.1992.tb00891.x.
32. Rodrigues ML, Alvarez M, Fonseca FL, Casadevall A. 2008. Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot. Cell 7:602-609. http://dx.doi.org/10.1128/EC.00307-07.
33. Meikle PJ, Hoogenraad NJ, Bonig I, Clarke AE, Stone BA. 1994. A (1-3,1-4)-beta-glucan-specific monoclonal antibody and its use in the quantitation and immunocytochemical location of (1-3,1-4)-betaglucans. Plant J. 5:1-9. http://dx.doi.org/10.1046/j.1365-313X.1994.5010001.x.
34. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. 2008. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10:2043-2057. http://dx.doi.org/10. 1111/j.1462-5822.2008.01186.x.
35. Cotter G, Doyle S, Kavanagh K. 2000. Development of an insect model for the in vivo pathogenicity testing of yeasts. FEMS Immunol. Med. Microbiol. 27:163-169. http://dx.doi.org/10.1111/j.1574-695X.2000.tb01427.x.
36. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. 2010. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 1:475-482. http://dx.doi.org/10.4161/viru.1.6.12985.
37. Bidla G, Hauling T, Dushay MS, Theopold U. 2009. Activation of insect phenoloxidase after injury: endogenous versus foreign elicitors. J. Innate Immun. 1:301-308. http://dx.doi.org/10.1159/000168009.
38. Desalermos A, Fuchs BB, Mylonakis E. 2012. Selecting an invertebrate model host for the study of fungal pathogenesis. PLoS Pathog. 8:e1002451. http://dx.doi.org/10.1371/journal.ppat.1002451.
39. Fuchs BB, Mylonakis E. 2006. Using non-mammalian hosts to study fungal virulence and host defense. Curr. Opin. Microbiol. 9:346-351. http://dx.doi.org/10.1016/j.mib.2006.06.004.
40. Mesa-Arango AC, Forastiero A, Bernal-Martinez L, Cuenca-Estrella M, Mellado E, Zaragoza O. 2013. The non-mammalian host Galleria mellonella can be used to study the virulence of the fungal pathogen Candida tropicalis and the efficacy of antifungal drugs during infection by this pathogenic yeast. Med. Mycol. 51:461-472. http://dx.doi.org/10.3109/13693786.2012.737031.
41. Cabib E, Roh DH, Schmidt M, Crotti LB, Varma A. 2001. The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J. Biol. Chem. 276:19679-19682. http://dx.doi.org/10.1074/jbc.R000031200.
42. Wheeler RT, Fink GR. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2:e35. http://dx.doi.org/10.1371/journal. ppat.0020035.
43. Wheeler RT, Kombe D, Agarwala SD, Fink GR. 2008. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog. 4:e1000227. http://dx.doi.org/10.1371/journal.ppat. 1000227.
44. Berman J. 2006. Morphogenesis and cell cycle progression in Candida albicans. Curr. Opin. Microbiol. 9:595-601. http://dx.doi.org/10.1016/j.mib. 2006.10.007.
45. Lionakis MS, Netea MG. 2013. Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog. 9:e1003079. http://dx.doi.org/10.1371/journal.ppat.1003079.
46. Lenardon MD, Munro CA, Gow NA. 2010. Chitin synthesis and fungal pathogenesis. Curr. Opin. Microbiol. 13:416-423. http://dx.doi.org/10.1016/j. mib.2010.05.002.
47. Lavine MD, Strand MR. 2002. Insect hemocytes and their role in immunity. Insect Biochem. Mol. Biol. 32:1295-1309. http://dx.doi.org/10.1016/S0965- 1748(02)00092-9.
48. Clemons KV, Espiritu M, Parmar R, Stevens DA. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297. http://dx.doi.org/10.1128/AAC.50.4.1293-1297.2006.
49. Ferreira JA, Carr JH, Starling CE, de Resende MA, Donlan RM. 2009. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob. Agents Chemother. 53: 4377-4384. http://dx.doi.org/10.1128/AAC.00316-09.
50. Melo AS, Colombo AL, Arthington-Skaggs BA. 2007. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51:3081-3088. http://dx.doi.org/10.1128/AAC.00676-07.
51. Carratala J. 2002. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clin. Microbiol. Infect. 8:282-289. http://dx.doi.org/10.1046/j.1469-0691.2002.00388.x.
52. Cateau E, Rodier MH, Imbert C. 2008. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J. Antimicrob. Chemother. 62:153-155. http://dx.doi.org/10.1093/jac/dkn160.
53. Cocuaud C, Rodier MH, Daniault G, Imbert C. 2005. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J. Antimicrob. Chemother. 56:507-512. http://dx.doi.org/10.1093/jac/dki269.
54. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48:1676-1684. http://dx.doi.org/10.1086/598933.
55. Cornely OA, Vehreschild JJ, Vehreschild MJ, Wurthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH. 2011. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob. Agents Chemother. 55: 5798-5803. http://dx.doi.org/ 10.1128/AAC.05134-11.